A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
EudraCT / EU CT No
2024-515279-37-00
Protocol No
CA088-1007
Trial information
Medical condition
Relapsed or refractory, lenalidomide-exposed multiple myeloma
Trial phase
Phase 3
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Start date
12/03/2025
End date
Recruiting
Main objective
Compare efficacy and safety of arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR-T therapy, with standard regimens.
Locations and Contact points
Greece
Site city
Organisation name
Department name
Name
Email
Telephone number
Chaidari
Attikon University General Hospital
Evangelos Terpos
+30 693 743 7111
Evangelos Terpos
+30 693 743 7111
Patras
University Hospital of Patras
Alexandros Spyridonidis
+302613604169
Cookies and your privacy
We use essential cookies to make this site work. With your consent, we also use Google Analytics cookies to measure visits and improve the site. You can change your choice at any time.